Topgolf Callaway and Others See Analyst Upgrades with Significant Price Target Increases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: Benzinga
- Topgolf Callaway Upgrade: Keybanc analyst Noah Zatzkin upgraded Topgolf Callaway Brands Corp. (NYSE:MODG) from Sector Weight to Overweight with a price target of $17, indicating a significant increase from its Thursday closing price of $14.68, reflecting optimism about future growth.
- Rocket Lab Price Target Increase: Morgan Stanley analyst Kristine Liwag upgraded Rocket Lab Corp. (NASDAQ:RKLB) from Equal-Weight to Overweight and raised the price target from $67 to $105, demonstrating confidence in its market performance, with shares closing at $90.76 on Thursday.
- Grab Holdings Rating Change: HSBC analyst Piyush Choudhary upgraded Grab Holdings Ltd. (NASDAQ:GRAB) from Hold to Buy with a price target of $6.2, a notable increase from its Thursday closing price of $4.39, indicating a positive outlook on its future business development.
- BioNTech Price Target Upgrade: Goldman Sachs analyst Asad Haider upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and raised the price target from $115 to $142, reflecting confidence in its product prospects, with shares closing at $106.07 on Thursday.
Analyst Views on BNTX
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 106.070
Low
116.00
Averages
141.93
High
181.00
Current: 106.070
Low
116.00
Averages
141.93
High
181.00
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
